Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Research article

High plasma levels of pro-inflammatory factors interleukin-17 and interleukin-23 are associated with poor outcome of cardiac-arrest patients: a single center experience

Authors: Yu-Gang Zhuang, Yuan-Zhuo Chen, Shu-Qin Zhou, Hu Peng, Yan-Qing Chen, Dong-Jie Li

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

Systemic inflammation is an important feature of post-cardiac arrest syndrome (PCAS). This study was designed to determine whether the plasma concentrations of some circulating pro-inflammatory cytokines (interleukin-17 [IL-8], IL-22, IL-23 and IL-33) are of value in predicting the outcome of patients after return of spontaneous circulation (ROSC) during the post–cardiac arrest period.

Methods

This was a prospective observational clinical study. In total, 21 patients (survivors, n = 10; non-survivors, n = 11) who experienced cardiac arrest and successful ROSC with expected survival of at least 7 days were consecutively enrolled from January 2016 to December 2017. Of the 21 enrolled patients, ten survived were designated “survivors”. The other eleven patients died between 2 days and 1 months post ROSC. Venous blood was drawn at three time-points: baseline (< 1 h post ROSC), 2 days post ROSC and 7 days post ROSC. Plasma IL-8, IL-22, IL-23 and IL-33 were determined using commercial enzyme-linked immunosorbent assays.

Results

Plasma creatinine levels, but aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, were elevated in non-survivors compared with survivors. Plasma levels of IL-17, IL-22, IL-23 and IL-33 of the 21 total patients did not change at 2 or 7 days post ROSC compared to baseline. In survivors, the plasma levels of IL-17 and IL-23 at 2 or 7 days post ROSC were lower than baseline. In non-survivors, plasma levels of IL-17 increased compared with baseline. Receiver operating characteristic curve analysis showed that the plasma levels of IL-17 and IL-23 at 2 or 7 days post ROSC were able to predict the mortality of PCAS patients, and positively correlated with Acute Physiology and Chronic Health Evaluation (APACHE)-II score and time to ROSC.

Conclusion

These results provide the first evidence that the elevated plasma IL-17 and IL-23 levels are associated with poor outcome in PCAS patients. The role of IL-17/IL-23 axis post ROSC is worth paying attention to in PCAS patients.

Trial registration

Appendix
Available only for authorised users
Literature
1.
Perkins GD, Jacobs IG, Nadkarni VM, Berg RA, Bhanji F, Biarent D, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update of the Utstein Resuscitation Registry Templates for Out-of-Hospital Cardiac Arrest: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia); and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. 2015;132:1286–300.PubMedCrossRef
2.
Hypothermia after Cardiac Arrest Study G. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–56.CrossRef
3.
Chan PS, Berg RA. Tang Y, Curtis LH, Spertus JA, American Heart Association's get with the guidelines-resuscitation I. association between therapeutic hypothermia and survival after in-hospital cardiac arrest. JAMA. 2016;316:1375–82.PubMedPubMedCentralCrossRef
4.
Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Bbttiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication: a scientific statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke (Part II). Int Emerg Nurs. 2010;18:8–28.PubMedCrossRef
5.
Ujvarosy D, Sebestyen V, Pataki T, Otvos T, Lorincz I, Paragh G, Szabo Z. Cardiovascular risk factors differently affect the survival of patients undergoing manual or mechanical resuscitation. BMC Cardiovasc Disord. 2018;18:227.PubMedPubMedCentralCrossRef
6.
Donnino MW, Miller J, Goyal N, Loomba M, Sankey SS, Dolcourt B, Sherwin R, Otero R, Wira C. Effective lactate clearance is associated with improved outcome in post-cardiac arrest patients. Resuscitation. 2007;75:229–34.PubMedCrossRef
7.
Donnino MW, Andersen LW, Giberson T, Gaieski DF, Abella BS, Peberdy MA, Rittenberger JC, Callaway CW, Ornato J, Clore J, Grossestreuer A, Salciccioli J, Cocchi MN. National Post-Arrest Research C. initial lactate and lactate change in post-cardiac arrest: a multicenter validation study. Crit Care Med. 2014;42:1804–11.PubMedPubMedCentralCrossRef
8.
Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Mutschler W, Jochum M. Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. Crit Care Med. 2002;30:2669–74.PubMedCrossRef
9.
Streitberger KJ, Leithner C, Wattenberg M, Tonner PH, Hasslacher J, Joannidis M, Pellis T, Di Luca E, Fodisch M, Krannich A, Ploner CJ, Storm C. Neuron-specific Enolase predicts poor outcome after cardiac arrest and targeted temperature management: a multicenter study on 1,053 patients. Crit Care Med. 2017;45:1145–51.PubMedCrossRef
10.
Kaneko T, Fujita M, Ogino Y, Yamamoto T, Tsuruta R, Kasaoka S. Serum neutrophil gelatinase-associated lipocalin levels predict the neurological outcomes of out-of-hospital cardiac arrest victims. BMC Cardiovasc Disord. 2017;17:111.PubMedPubMedCentralCrossRef
11.
Bro-Jeppesen J, Kjaergaard J, Wanscher M, Nielsen N, Friberg H, Bjerre M, Hassager C. Systemic inflammatory response and potential prognostic implications after out-of-hospital cardiac arrest: a substudy of the target temperature management trial. Crit Care Med. 2015;43:1223–32.PubMedCrossRef
12.
Bro-Jeppesen J, Kjaergaard J, Stammet P, Wise MP, Hovdenes J, Aneman A, et al. Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature management at 33 degrees C or 36 degrees C. Resuscitation. 2016;98:1–8.PubMedCrossRef
13.
Chen S, Wang Z, Xu B, Mi X, Sun W, Quan N, Wang L, Chen X, Liu Q, Zheng Y, Leng J, Li J. The modulation of cardiac contractile function by the pharmacological and toxicological effects of Urocortin2. Toxicol Sci. 2015;148:581–93.PubMedPubMedCentralCrossRef
14.
Li C, Gao Y, Tian J, Xing Y, Zhu H, Shen J. Long-term oral Asperosaponin VI attenuates cardiac dysfunction, myocardial fibrosis in a rat model of chronic myocardial infarction. Food Chem Toxicol. 2012;50:1432–8.PubMedCrossRef
15.
Siemian JN, Wang K, Zhang Y, Li JX. Mechanisms of imidazoline I2 receptor agonist-induced antinociception in rats: involvement of monoaminergic neurotransmission. Br J Pharmacol. 2018;175:1519–34.PubMedPubMedCentralCrossRef
16.
Zhang C, Deng J, Liu D, Tuo X, Xiao L, Lai B, Yao Q, Liu J, Yang H, Wang N. Nuciferine ameliorates hepatic steatosis in high-fat diet/streptozocin-induced diabetic mice through a PPARalpha/PPARgamma coactivator-1alpha pathway. Br J Pharmacol. 2018;175:4218–28.PubMedPubMedCentralCrossRef
17.
Liu J, Jin X, Zhou F, Chen H, Wang W, Liu Y, Wang G, Hao K, Zhang J. Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: a new strategy for CYP3A-mediated drug hepatotoxicity. Br J Pharmacol. 2020;177:1538–55.PubMedCrossRef
18.
Wei CC, Kong YY, Hua X, Li GQ, Zheng SL, Cheng MH, Wang P, Miao CY. NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia. Br J Pharmacol. 2017;174:3823–36.PubMedPubMedCentralCrossRef
19.
Feng L, Sun Y, Song P, Xu L, Wu X, Wu X, Shen Y, Sun Y, Kong L, Wu X, Xu Q. Seselin ameliorates inflammation via targeting Jak2 to suppress the proinflammatory phenotype of macrophages. Br J Pharmacol. 2019;176:317–33.PubMedCrossRef
20.
Li DJ, Liu J, Hua X, Fu H, Huang F, Fei YB, Lu WJ, Shen FM, Wang P. Nicotinic acetylcholine receptor alpha7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease. Metabolism. 2018;79:52–63.PubMedCrossRef
21.
Li DJ, Li YH, Yuan HB, Qu LF, Wang P. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017;68:31–42.PubMedCrossRef
22.
Li DJ, Tong J, Li YH, Meng HB, Ji QX, Zhang GY, Zhu JH, Zhang WJ, Zeng FY, Huang G, Hua X, Shen FM, Wang P. Melatonin safeguards against fatty liver by antagonizing TRAFs-mediated ASK1 deubiquitination and stabilization in a beta-arrestin-1 dependent manner. J Pineal Res. 2019;67:e12611.PubMed
23.
Li DJ, Tong J, Zeng FY, Guo M, Li YH, Wang H, Wang P. Nicotinic ACh receptor alpha7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3. Br J Pharmacol. 2019;176:4388–401.PubMedCrossRef
24.
Lv G, Sun D, Zhang J, Xie X, Wu X, Fang W, Tian J, Yan C, Wang H, Fu F. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharm Sin B. 2017;7:52–8.PubMedCrossRef
25.
He Y, Zhang W, Guo T, Zhang G, Qin W, Zhang L, Wang C, Zhu W, Yang M, Hu X, Singh V, Wu L, Gref R, Zhang J. Drug nanoclusters formed in confined nano-cages of CD-MOF: dramatic enhancement of solubility and bioavailability of azilsartan. Acta Pharm Sin B. 2019;9:97–106.PubMedCrossRef
26.
Donnino MW, Salciccioli JD, Dejam A, Giberson T, Giberson B, Cristia C, Gautam S, Cocchi MN. APACHE II scoring to predict outcome in post-cardiac arrest. Resuscitation. 2013;84:651–6.PubMedCrossRef
27.
28.
Chen Y, Zhang QS, Shao QH, Wang S, Yuan YH, Chen NH, Wang HB. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. Acta Pharmacol Sin. 2019;40:991–8.PubMedCrossRef
29.
Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Int Immunopharmacol. 2019;67:458–64.PubMedCrossRef
30.
Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L. Reactive oxygen species: key regulators in vascular health and diseases. Br J Pharmacol. 2018;175:1279–92.PubMedCrossRef
31.
Wang S, Binder P, Fang Q, Wang Z, Xiao W, Liu W, Wang X. Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets. Br J Pharmacol. 2018;175:1293–304.PubMedCrossRef
32.
33.
Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, Fraisse F, Dinh-Xuan AT, Carli P, Spaulding C, Dhainaut JF, Cavaillon JM. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation. 2002;106:562–8.PubMedCrossRef
34.
Niemann JT, Rosborough JP, Youngquist S, Shah AP, Lewis RJ, Phan QT, Filler SG. Cardiac function and the proinflammatory cytokine response after recovery from cardiac arrest in swine. J Interf Cytokine Res. 2009;29:749–58.CrossRef
35.
Peberdy MA, Andersen LW, Abbate A, Thacker LR, Gaieski D, Abella BS, Grossestreuer AV, Rittenberger JC, Clore J, Ornato J, Cocchi MN, Callaway C, Donnino M. National Post Arrest Research Consortium I. inflammatory markers following resuscitation from out-of-hospital cardiac arrest-a prospective multicenter observational study. Resuscitation. 2016;103:117–24.PubMedCrossRef
36.
Yang L, Wang J, Deng Y, Gong C, Li Q, Chen Q, Li H, Jiang C, Zhou R, Hai K, Wu W, Li T. Melatonin improves neurological outcomes and preserves hippocampal mitochondrial function in a rat model of cardiac arrest. PLoS One. 2018;13:e0207098.PubMedPubMedCentralCrossRef
37.
Schilperoort M, van den Berg R, Bosmans LA, van Os BW, Dolle MET, Smits NAM, et al. Disruption of circadian rhythm by alternating light-dark cycles aggravates atherosclerosis development in APOE*3-Leiden.CETP mice. J Pineal Res. 2020;68:e12614.PubMedCrossRef
38.
Zhou H, Li D, Zhu P, Ma Q, Toan S, Wang J, Hu S, Chen Y, Zhang Y. Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-CypD-mPTP pathway attenuates cardiac microvascular ischemia-reperfusion injury. J Pineal Res. 2018;65:e12503.PubMedCrossRef
39.
Huang CC, Chiou CH, Liu SC, Hu SL, Su CM, Tsai CH, Tang CH. Melatonin attenuates TNF-alpha and IL-1beta expression in synovial fibroblasts and diminishes cartilage degradation: implications for the treatment of rheumatoid arthritis. J Pineal Res. 2019;66:e12560.PubMedCrossRef
40.
Gul-Kahraman K, Yilmaz-Bozoglan M, Sahna E. Physiological and pharmacological effects of melatonin on remote ischemic perconditioning after myocardial ischemia-reperfusion injury in rats: role of Cybb, Fas, NfkappaB, Irisin signaling pathway. J Pineal Res. 2019;67:e12589.PubMedCrossRef
41.
Han D, Wang Y, Chen J, Zhang J, Yu P, Zhang R, Li S, Tao B, Wang Y, Qiu Y, Xu M, Gao E, Cao F. Activation of melatonin receptor 2 but not melatonin receptor 1 mediates melatonin-conferred cardioprotection against myocardial ischemia/reperfusion injury. J Pineal Res. 2019;67:e12571.PubMedCrossRef
42.
Zhang Y, Wang Y, Xu J, Tian F, Hu S, Chen Y, Fu Z. Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways. J Pineal Res. 2019;66:e12542.PubMedCrossRef
43.
Lochner A, Marais E, Huisamen B. Melatonin and cardioprotection against ischaemia/reperfusion injury: What's new? A review. J Pineal Res. 2018;65:e12490.PubMedCrossRef
44.
Prado NJ, Egan Benova T, Diez ER, Knezl V, Liptak B, Ponce Zumino AZ, Llamedo-Soria M, Szeiffova Bacova B, Miatello RM, Tribulova N. Melatonin receptor activation protects against low potassium-induced ventricular fibrillation by preserving action potentials and connexin-43 topology in isolated rat hearts. J Pineal Res. 2019;67:e12605.PubMedCrossRef
45.
Xu L, Su Y, Zhao Y, Sheng X, Tong R, Ying X, Gao L, Ji Q, Gao Y, Yan Y, Yuan A, Wu F, Lan F, Pu J. Melatonin differentially regulates pathological and physiological cardiac hypertrophy: crucial role of circadian nuclear receptor RORalpha signaling. J Pineal Res. 2019;67:e12579.PubMed
46.
Misaka T, Yoshihisa A, Yokokawa T, Sato T, Oikawa M, Kobayashi A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Takeishi Y. Plasma levels of melatonin in dilated cardiomyopathy. J Pineal Res. 2019;66:e12564.PubMedPubMedCentralCrossRef
47.
Ding M, Ning J, Feng N, Li Z, Liu Z, Wang Y, Wang Y, Li X, Huo C, Jia X, Xu R, Fu F, Wang X, Pei J. Dynamin-related protein 1-mediated mitochondrial fission contributes to post-traumatic cardiac dysfunction in rats and the protective effect of melatonin. J Pineal Res. 2018;64.
48.
Ding M, Feng N, Tang D, Feng J, Li Z, Jia M, Liu Z, Gu X, Wang Y, Fu F, Pei J. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1alpha pathway. J Pineal Res. 2018;65:e12491.PubMedPubMedCentralCrossRef
49.
Cristiano C, Volpicelli F, Lippiello P, Buono B, Raucci F, Piccolo M, Iqbal AJ, Irace C, Miniaci MC, Perrone Capano C, Calignano A, Mascolo N, Maione F. Neutralization of IL-17 rescues amyloid-beta-induced neuroinflammation and memory impairment. Br J Pharmacol. 2019;176:3544–57.PubMedCrossRef
50.
Alvarez-Sanchez N, Cruz-Chamorro I, Lopez-Gonzalez A, Utrilla JC, Fernandez-Santos JM, Martinez-Lopez A, Lardone PJ, Guerrero JM, Carrillo-Vico A. Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun. 2015;50:101–14.PubMedCrossRef
51.
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763–76.PubMedCrossRef
52.
53.
Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL, Okusa MD. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120:331–42..PubMedCrossRef
54.
Yan X, Shichita T, Katsumata Y, Matsuhashi T, Ito H, Ito K, et al. Deleterious effect of the IL-23/IL-17A axis and gammadeltaT cells on left ventricular remodeling after myocardial infarction. J Am Heart Assoc. 2012;1:e004408.PubMedPubMedCentral
55.
Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, Iwaki T, Okada Y, Iida M, Cua DJ, Iwakura Y, Yoshimura A. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946–50.PubMedCrossRef
56.
Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793–802.PubMedCrossRef
57.
Wang K, Wen S, Jiao J, Tang T, Zhao X, Zhang M, et al. IL-21 promotes myocardial ischaemia/reperfusion injury through the modulation of neutrophil infiltration. Br J Pharmacol. 2018;175:1329–43.PubMedCrossRef
58.
An W, Yu Y, Zhang Y, Zhang Z, Yu Y, Zhao X. Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction. Br J Pharmacol. 2019;176:699–710.PubMedPubMedCentralCrossRef
59.
Guo J, Wang H, Li L, Yuan Y, Shi X, Hou S. Treatment with IL-19 improves locomotor functional recovery after contusion trauma to the spinal cord. Br J Pharmacol. 2018;175:2611–21.PubMedPubMedCentralCrossRef
60.
Weiser C, Schwameis M, Sterz F, Herkner H, Lang IM, Schwarzinger I, Spiel AO. Mortality in patients resuscitated from out-of-hospital cardiac arrest based on automated blood cell count and neutrophil lymphocyte ratio at admission. Resuscitation. 2017;116:49–55.PubMedCrossRef
61.
Patel VH, Vendittelli P, Garg R, Szpunar S, LaLonde T, Lee J, Rosman H, Mehta RH, Othman H. Neutrophil-lymphocyte ratio: a prognostic tool in patients with in-hospital cardiac arrest. World J Crit Care Med. 2019;8:9–17.PubMedPubMedCentralCrossRef
62.
Dell'anna AM, Bini Viotti J, Beumier M, Orbegozo-Cortes D, Donadello K, Scolletta S, Vincent JL, Taccone FS. C-reactive protein levels after cardiac arrest in patients treated with therapeutic hypothermia. Resuscitation. 2014;85:932–8.PubMedCrossRef
63.
Oppert M, Reinicke A, Muller C, Barckow D, Frei U, Eckardt KU. Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation. 2002;53:167–70.PubMedCrossRef
64.
Mukherjee S, Allen RM, Lukacs NW, Kunkel SL, Carson WF. STAT3-mediated IL-17 production by postseptic T cells exacerbates viral immunopathology of the lung. Shock. 2012;38:515–23.PubMedPubMedCentralCrossRef
65.
Wynn JL, Wilson CS, Hawiger J, Scumpia PO, Marshall AF, Liu JH, et al. Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proc Natl Acad Sci U S A. 2016;113:E2627–35.PubMedPubMedCentralCrossRef
66.
Belladonna ML, Vacca C, Volpi C, Giampietri A, Fioretti MC, Puccetti P, Grohmann U, Campanile F. IL-23 neutralization protects mice from gram-negative endotoxic shock. Cytokine. 2006;34:161–9.PubMedCrossRef
67.
Wenzel UO, Bode M, Kurts C, Ehmke H. Salt, inflammation, IL-17 and hypertension. Br J Pharmacol. 2019;176:1853–63.PubMedCrossRef
68.
Paradis NA, Wenzel V, Southall J. Pressor drugs in the treatment of cardiac arrest. Cardiol Clin 2002;20:61–78, viii.
69.
Kern KB, Elchisak MA, Sanders AB, Badylak SF, Tacker WA, Ewy GA. Plasma catecholamines and resuscitation from prolonged cardiac arrest. Crit Care Med. 1989;17:786–91.PubMedCrossRef
70.
Wu J, Wang S, Li C. Hemodynamic and catecholamine changes after recurrent ventricular fibrillation. J Emerg Med. 2013;44:543–9.PubMedCrossRef
Metadata
Title
High plasma levels of pro-inflammatory factors interleukin-17 and interleukin-23 are associated with poor outcome of cardiac-arrest patients: a single center experience
Authors
Yu-Gang Zhuang
Yuan-Zhuo Chen
Shu-Qin Zhou
Hu Peng
Yan-Qing Chen
Dong-Jie Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01451-y

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue

Research article

Identifying Phenogroups in patients with subclinical diastolic dysfunction using unsupervised statistical learning

Research article

Association of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of carotid atherosclerosis: a cross-sectional analysis of 730 Chinese Han adults in Chongqing

Research article

BRD4 and PIN1 gene polymorphisms are associated with high pulse pressure risk in a southeastern Chinese population

Research article

N-terminal pro-B-type natriuretic peptide as a prognostic indicator for 30-day mortality following out-of-hospital cardiac arrest: a prospective observational study

Research article

Acute decompensated heart failure in a non cardiology tertiary referral centre, Sarawak General Hospital (SGH-HF)

Research article

Association between the ratio of serum n-3 to n-6 polyunsaturated fatty acids and acute coronary syndrome in non-obese patients with coronary risk factor: a multicenter cross-sectional study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits